Amedisys (AMED)
(Delayed Data from NSDQ)
$96.12 USD
+0.08 (0.08%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $96.15 +0.03 (0.03%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth C Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$96.12 USD
+0.08 (0.08%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $96.15 +0.03 (0.03%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth C Momentum A VGM
Zacks News
Omnicell Continues to Pursue Buyouts, Costs on the Rise
by Zacks Equity Research
Omnicell (OMCL) progresses well with its strategy to grow inorganically. Rising operating expenses a concern.
Cardiovascular Systems Portfolio Strong, Competition Rife
by Zacks Equity Research
Cardiovascular Systems (CSII) suffers a long history of net loss since its launch in 1989 with no immediate solution in sight.
Here's Why You Should Invest in Penumbra (PEN) Stock Now
by Zacks Equity Research
The market is quite upbeat about Penumbra's (PEN) recently-closed buyout of a controlling stake in MVI Health, aimed at capturing the great potential of virtual reality application.
Here's Why You Should Retain IDEXX (IDXX) in Your Portfolio
by Zacks Equity Research
IDEXX (IDXX) continues to see strong organic growth. Adverse currency movement is a concern.
Here's Why You Should Retain QIAGEN (QGEN) in Your Portfolio
by Zacks Equity Research
A tough competitive landscape and strong reliance on relationships with collaborative partners is a major deterrent to QIAGEN (QGEN). The company's increased focus on the NGS portfolio is a positive.
Genomic Health (GHDX) Hits a 52-Week High: What's Driving It?
by Zacks Equity Research
Genomic Health (GHDX) sees increasing private coverage for the Oncotype DX GPS test within the prostate cancer space.
4 Stocks to Bet on the Burgeoning Home Healthcare Industry
by Sapna Bagaria
Growing senior population, increasing chronic illness, high cost of treatment at inpatient settings and preference by patients drives demand for home health care.
Amedisys Ties Up With Medalogix to Boost Home Health Unit
by Zacks Equity Research
Amedisys (AMED) pursues deals to boost Home Health business.
Should First Trust Small Cap Growth AlphaDEX Fund (FYC) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FYC
Why Is Amedisys (AMED) Up 18.5% Since Last Earnings Report?
by Zacks Equity Research
Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
6 Top Stock Options for Millennials Right Now
by Awantika Poddar
Millennials is the term generally applicable to individuals whose birth years ranges between 1981 and 1996
Zacks.com featured highlights include: Vitamin Shoppe, North American Construction, Verso, Amedisys and Heidrick & Struggles
by Zacks Equity Research
Zacks.com featured highlights include: Vitamin Shoppe, North American Construction, Verso, Amedisys and Heidrick & Struggles
S&P 500 Tops 2,900: Best ETFs & Stocks of Best Sectors
by Sweta Killa
While nine of the S&P 500 sectors are performing well, information technology is leading the rally followed by consumer discretionary and healthcare.
5 Stocks With Relative Price Strength to Boost Your Returns
by Nilanjan Choudhury
Want to try an out-of-the-box approach to earn handsome returns? Tap these stocks with explosive relative price strength.
5 Mid-Cap Stocks For Growth Investors to Buy Right Now
by Awantika Poddar
Investing in mid-cap companies is a safe bet, especially during economic downturns and stringent credit conditions.
5 Growth Stocks at New Highs with Room for More Upside
by Sweta Killa
We have highlighted five growth stocks that hit all-time highs in the current market rally and will likely to continue to move higher given their superior fundamentals.
Here's Why You Should Add Amedisys (AMED) to Your Portfolio
by Zacks Equity Research
Amedisys (AMED) witnesses solid Medicare and non-Medicare revenues at Home Health and Hospice divisions. A favorable demographic trend bodes well.
Will Strong RTG Arm Shape Medtronic's (MDT) Q1 Earnings?
by Zacks Equity Research
Medtronic (MDT) poised to gain on continued growth in RTG business in Q1.
Will Solid Diabetes Arm Drive Medtronic's (MDT) Q1 Earnings?
by Zacks Equity Research
Medtronic (MDT) poised to gain on strength in Diabetes business in Q1 on continued uptake of MiniMed 670G system in the United States along with enhanced sensor supply capacity.
Haemonetics Strong on Plasma Unit Amid Blood Center Weakness
by Zacks Equity Research
Haemonetics (HAE) witnesses strong growth in Plasma franchise. Dullness in Blood Center business prevails.
Hologic Launches Fluent Fluid Management System, Widens Suite
by Zacks Equity Research
Hologic (HOLX) adopts initiatives to boost the GYN Surgical segment.
Amedisys (AMED) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Amedisys, Inc. (AMED).
Amedisys (AMED) Grows on Robust Home Health, Personal Care
by Zacks Equity Research
Amedisys' (AMED) solid performance in Personal Care division is impressive. Plus, a favorable demographic trend and calculating buyouts bode well for the company.
Here's Why You Should Invest in Align Technology (ALGN) Now
by Zacks Equity Research
We are upbeat about Align Technology's (ALGN) solid Invisalign Technology prospects and growth in North America and internationally.
Medtronic Launches IN.PACT Admiral in Japan, Boosts APV Arm
by Zacks Equity Research
Medtronic's (MDT) recent launch of IN.PACT Admiral DCB in Japan is expected to boost the top line.